HEADER:
Progeria Research Foundation Seeks Proposals for Research on Hutchinson-Gilford Progeria Syndrome (HGPS, or Progeria)

2017 Deadline:
September 19, 2017 for consideration at the December 2017 Board of Directors Meeting
Submission date subject to change. Please refer to PRF website for updates.
http://www.progeriaresearch.org/application-deadlines.html

The Progeria Research Foundation (PRF) is the only organization in the world dedicated to discovering treatments and the cure for Progeria and its aging-related disorders. Progeria is a rare, fatal, "premature aging" disease caused by the mutant protein called 'progerin'. Affected children exhibit excessive atherosclerosis and die at an average age of 14 years due to heart attacks or stroke. Studies have solidified biological links between Progeria, cardiovascular disease and aging, including the observation that progerin is expressed at low levels in cells and tissues from non-HGPS individuals.

PRF will consider proposals in all areas directly relevant to Progeria. Two priority areas are listed below:

1. **Discovery of biological markers of disease in HGPS that can be assessed in human and/or mouse samples**. Highest priority will be given to those markers that can be assayed in easily obtainable human samples such as blood, urine, and cheek swabs. In addition, proposals that explore biomarker relevance to disease process and/or change in markers with disease treatment are encouraged.

2. **Discovery and/or testing of candidate treatment compounds in both cell based and mouse models of HGPS.** Of note, proposals should test compounds in a progerin-producing mouse model as the priority. Comparisons to other mouse models of disease, such as ZMPSTE24-/- and other non-progerin producing mouse models are acceptable, but only as a comparison to progerin-producing models.

Visit the PRF Web site for complete program information: www.progeriaresearch.org

Awards are given in 3 categories (see LINK) with varying funding levels and lengths of time (up to three years). Projects must show promise for contributing to the scientific or clinical advancement in the field of Progeria.

Principal Investigators must hold post-doctoral positions or beyond. PI's wishing to have a project performed by a post-doctoral associate must act as co-principal investigators.

Awards will be granted only to applicants affiliated with institutions with 501(c)3 status, or the equivalent for foreign institutions.

RFP Link: http://www.progeriaresearch.org/grant_application.html or contact The Progeria Research Foundation at 978-535-2594 or researchgrants@progeriaresearch.org

KEY WORDS
Progeria, progeroid, aging, genetics, Lamin A, genetic disease, atherosclerosis, heart disease, stroke, cardiovascular disease, Werner syndrome, senescence, pediatric disease, stem cell, mouse model, telomere, LMNA, chromatin, translational science, progeroid syndrome, restrictive dermopathy, mandibuloacral dysplasia, laminopathy